| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Therapy | 177 | 2025 | 744 | 31.290 |
Why?
|
| Dependovirus | 164 | 2024 | 659 | 20.720 |
Why?
|
| Genetic Vectors | 166 | 2025 | 820 | 18.240 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 31 | 2024 | 63 | 9.990 |
Why?
|
| alpha 1-Antitrypsin | 42 | 2024 | 88 | 8.550 |
Why?
|
| Gene Editing | 20 | 2024 | 301 | 6.330 |
Why?
|
| Gene Transfer Techniques | 49 | 2025 | 307 | 6.140 |
Why?
|
| Cystic Fibrosis | 45 | 2018 | 108 | 6.000 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 43 | 2016 | 75 | 4.970 |
Why?
|
| Transduction, Genetic | 33 | 2022 | 233 | 3.510 |
Why?
|
| Humans | 227 | 2025 | 60093 | 2.880 |
Why?
|
| Transgenes | 24 | 2023 | 176 | 2.740 |
Why?
|
| Muscular Dystrophy, Duchenne | 5 | 2023 | 43 | 2.710 |
Why?
|
| Animals | 168 | 2025 | 19752 | 2.580 |
Why?
|
| CRISPR-Cas Systems | 11 | 2024 | 332 | 2.410 |
Why?
|
| Cell- and Tissue-Based Therapy | 7 | 2021 | 38 | 2.370 |
Why?
|
| Dystrophin | 3 | 2023 | 35 | 1.950 |
Why?
|
| Science | 3 | 2021 | 34 | 1.910 |
Why?
|
| Capsid | 11 | 2019 | 89 | 1.740 |
Why?
|
| Adenoviridae | 16 | 2021 | 120 | 1.610 |
Why?
|
| Mice | 83 | 2022 | 10331 | 1.490 |
Why?
|
| Clinical Trials as Topic | 14 | 2021 | 443 | 1.480 |
Why?
|
| Liver | 19 | 2021 | 788 | 1.440 |
Why?
|
| Interleukin-10 | 15 | 2010 | 147 | 1.430 |
Why?
|
| Immunotherapy | 3 | 2019 | 235 | 1.430 |
Why?
|
| Societies, Medical | 6 | 2020 | 342 | 1.370 |
Why?
|
| Gene Expression | 25 | 2020 | 807 | 1.320 |
Why?
|
| Lung | 22 | 2024 | 842 | 1.310 |
Why?
|
| DNA, Recombinant | 14 | 2013 | 45 | 1.310 |
Why?
|
| Peer Review, Research | 2 | 2020 | 46 | 1.290 |
Why?
|
| Central Nervous System Diseases | 3 | 2024 | 56 | 1.270 |
Why?
|
| Severe Combined Immunodeficiency | 4 | 2018 | 52 | 1.250 |
Why?
|
| Lung Diseases | 8 | 2017 | 166 | 1.250 |
Why?
|
| Genetic Diseases, Inborn | 4 | 2018 | 37 | 1.210 |
Why?
|
| Muscular Diseases | 3 | 2019 | 47 | 1.090 |
Why?
|
| History, 20th Century | 8 | 2025 | 230 | 1.080 |
Why?
|
| Mutation | 20 | 2024 | 2466 | 1.080 |
Why?
|
| Mice, Inbred C57BL | 37 | 2018 | 3220 | 1.070 |
Why?
|
| Recombinant Proteins | 7 | 2018 | 697 | 1.060 |
Why?
|
| T-Lymphocytes | 7 | 2020 | 969 | 1.040 |
Why?
|
| DNA | 6 | 2019 | 793 | 1.010 |
Why?
|
| Education, Medical | 2 | 2018 | 178 | 0.990 |
Why?
|
| Physicians | 2 | 2021 | 442 | 0.990 |
Why?
|
| Injections, Intramuscular | 15 | 2020 | 69 | 0.990 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 12 | 2017 | 448 | 0.990 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2023 | 20 | 0.980 |
Why?
|
| Research Subjects | 2 | 2021 | 38 | 0.980 |
Why?
|
| Injections, Spinal | 4 | 2024 | 43 | 0.980 |
Why?
|
| Capsid Proteins | 5 | 2020 | 93 | 0.980 |
Why?
|
| Central Nervous System | 4 | 2024 | 193 | 0.970 |
Why?
|
| History, 21st Century | 7 | 2025 | 166 | 0.970 |
Why?
|
| Lentivirus | 5 | 2017 | 62 | 0.950 |
Why?
|
| Hepatocytes | 8 | 2024 | 195 | 0.950 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2017 | 280 | 0.940 |
Why?
|
| Tay-Sachs Disease | 2 | 2022 | 34 | 0.930 |
Why?
|
| Recombination, Genetic | 9 | 2008 | 237 | 0.860 |
Why?
|
| Neuroimaging | 1 | 2024 | 131 | 0.850 |
Why?
|
| Genetic Engineering | 4 | 2019 | 112 | 0.830 |
Why?
|
| Green Fluorescent Proteins | 14 | 2017 | 354 | 0.830 |
Why?
|
| Muscle, Skeletal | 14 | 2024 | 678 | 0.820 |
Why?
|
| Lipid Metabolism, Inborn Errors | 3 | 2019 | 14 | 0.810 |
Why?
|
| Nervous System Diseases | 1 | 2024 | 105 | 0.810 |
Why?
|
| Immunoglobulin E | 5 | 2010 | 85 | 0.810 |
Why?
|
| Biomedical Research | 3 | 2023 | 253 | 0.800 |
Why?
|
| Gene Expression Regulation | 10 | 2019 | 1538 | 0.800 |
Why?
|
| Pseudomonas aeruginosa | 6 | 2010 | 100 | 0.780 |
Why?
|
| Congresses as Topic | 3 | 2017 | 74 | 0.780 |
Why?
|
| DNA, Viral | 10 | 2010 | 228 | 0.770 |
Why?
|
| Liver Diseases | 4 | 2017 | 136 | 0.760 |
Why?
|
| Students, Medical | 4 | 2020 | 246 | 0.760 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2022 | 21 | 0.760 |
Why?
|
| Hypersensitivity | 4 | 2012 | 63 | 0.760 |
Why?
|
| Health Policy | 2 | 2020 | 183 | 0.750 |
Why?
|
| Genes, Reporter | 12 | 2019 | 243 | 0.750 |
Why?
|
| Disease Models, Animal | 20 | 2022 | 2078 | 0.740 |
Why?
|
| beta-Thalassemia | 1 | 2021 | 13 | 0.740 |
Why?
|
| Tropism | 2 | 2021 | 17 | 0.740 |
Why?
|
| Community Health Services | 1 | 2022 | 128 | 0.730 |
Why?
|
| Mitochondrial Diseases | 3 | 2019 | 22 | 0.730 |
Why?
|
| Amyloidosis | 1 | 2021 | 60 | 0.710 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 3 | 2012 | 9 | 0.710 |
Why?
|
| Licensure | 1 | 2020 | 14 | 0.710 |
Why?
|
| Myopathies, Structural, Congenital | 1 | 2020 | 2 | 0.710 |
Why?
|
| Epithelial Cells | 10 | 2005 | 376 | 0.700 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2020 | 5 | 0.700 |
Why?
|
| Transfection | 19 | 2021 | 676 | 0.700 |
Why?
|
| RNA Interference | 4 | 2017 | 592 | 0.690 |
Why?
|
| Professional-Family Relations | 1 | 2021 | 89 | 0.690 |
Why?
|
| Ethics, Medical | 2 | 2019 | 38 | 0.680 |
Why?
|
| Genital Neoplasms, Female | 1 | 2020 | 19 | 0.680 |
Why?
|
| Chronic Traumatic Encephalopathy | 1 | 2020 | 5 | 0.680 |
Why?
|
| Inflammation | 10 | 2020 | 1111 | 0.680 |
Why?
|
| Adenosine Deaminase | 2 | 2011 | 16 | 0.670 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2021 | 92 | 0.670 |
Why?
|
| Recombinational DNA Repair | 1 | 2019 | 20 | 0.670 |
Why?
|
| Faculty, Medical | 2 | 2021 | 203 | 0.660 |
Why?
|
| Racism | 1 | 2021 | 82 | 0.660 |
Why?
|
| Retina | 5 | 2018 | 119 | 0.650 |
Why?
|
| Ethics, Research | 1 | 2019 | 20 | 0.650 |
Why?
|
| Family | 1 | 2021 | 224 | 0.640 |
Why?
|
| Rare Diseases | 2 | 2022 | 38 | 0.640 |
Why?
|
| Cell Line | 24 | 2012 | 2018 | 0.630 |
Why?
|
| Pandemics | 2 | 2021 | 629 | 0.630 |
Why?
|
| Gene Expression Profiling | 5 | 2012 | 712 | 0.620 |
Why?
|
| Embryo, Mammalian | 1 | 2019 | 161 | 0.610 |
Why?
|
| Virus Internalization | 1 | 2019 | 99 | 0.610 |
Why?
|
| Low Back Pain | 1 | 2019 | 120 | 0.600 |
Why?
|
| Sexual Harassment | 1 | 2018 | 14 | 0.590 |
Why?
|
| Vaccines, DNA | 1 | 2018 | 98 | 0.580 |
Why?
|
| Human bocavirus | 1 | 2017 | 1 | 0.580 |
Why?
|
| Transposases | 1 | 2017 | 13 | 0.570 |
Why?
|
| Acyl-CoA Dehydrogenase, Long-Chain | 3 | 2019 | 10 | 0.570 |
Why?
|
| Sex Offenses | 1 | 2018 | 46 | 0.570 |
Why?
|
| Injections, Intravenous | 8 | 2017 | 149 | 0.560 |
Why?
|
| Antigens, CD19 | 1 | 2017 | 20 | 0.560 |
Why?
|
| Prescription Drug Misuse | 1 | 2017 | 21 | 0.560 |
Why?
|
| Vulnerable Populations | 1 | 2018 | 87 | 0.550 |
Why?
|
| Women's Health | 1 | 2020 | 390 | 0.550 |
Why?
|
| Emigration and Immigration | 1 | 2017 | 25 | 0.550 |
Why?
|
| Bronchi | 10 | 2004 | 79 | 0.550 |
Why?
|
| Federal Government | 1 | 2016 | 20 | 0.550 |
Why?
|
| Gene Drive Technology | 1 | 2016 | 1 | 0.540 |
Why?
|
| United States | 12 | 2023 | 7608 | 0.540 |
Why?
|
| Retinal Diseases | 1 | 2017 | 31 | 0.540 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2020 | 201 | 0.540 |
Why?
|
| Ecology | 1 | 2016 | 12 | 0.540 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2017 | 144 | 0.530 |
Why?
|
| Neutrophils | 4 | 2017 | 352 | 0.530 |
Why?
|
| Policy | 1 | 2016 | 48 | 0.530 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 332 | 0.530 |
Why?
|
| Polymerase Chain Reaction | 15 | 2010 | 498 | 0.530 |
Why?
|
| DNA Transposable Elements | 1 | 2017 | 126 | 0.530 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 351 | 0.530 |
Why?
|
| Islets of Langerhans | 7 | 2006 | 267 | 0.520 |
Why?
|
| Vaccination | 1 | 2018 | 342 | 0.510 |
Why?
|
| Female | 53 | 2021 | 31229 | 0.510 |
Why?
|
| Aspergillus fumigatus | 4 | 2012 | 37 | 0.500 |
Why?
|
| Patient Advocacy | 1 | 2015 | 32 | 0.500 |
Why?
|
| Health Personnel | 1 | 2019 | 343 | 0.500 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 48 | 0.500 |
Why?
|
| Macaca mulatta | 11 | 2024 | 247 | 0.500 |
Why?
|
| Epithelium | 8 | 2010 | 97 | 0.500 |
Why?
|
| Brain | 6 | 2024 | 1493 | 0.490 |
Why?
|
| Extremities | 1 | 2015 | 50 | 0.490 |
Why?
|
| Portal Vein | 4 | 2008 | 37 | 0.490 |
Why?
|
| Diabetes Mellitus, Type 1 | 7 | 2004 | 604 | 0.480 |
Why?
|
| Respiratory System | 2 | 2018 | 42 | 0.470 |
Why?
|
| Stem Cells | 4 | 2017 | 258 | 0.470 |
Why?
|
| Immunity | 3 | 2023 | 97 | 0.460 |
Why?
|
| Germ Cells | 1 | 2015 | 97 | 0.460 |
Why?
|
| Hyperlipoproteinemia Type I | 1 | 2014 | 1 | 0.460 |
Why?
|
| Immunohistochemistry | 9 | 2017 | 854 | 0.460 |
Why?
|
| Alcoholism | 1 | 2017 | 308 | 0.460 |
Why?
|
| Antibodies | 5 | 2023 | 176 | 0.450 |
Why?
|
| Recombinant Fusion Proteins | 7 | 2013 | 497 | 0.450 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 2 | 2011 | 6 | 0.450 |
Why?
|
| Cells, Cultured | 12 | 2017 | 2101 | 0.440 |
Why?
|
| Male | 48 | 2024 | 27963 | 0.430 |
Why?
|
| Health Care Costs | 1 | 2015 | 210 | 0.430 |
Why?
|
| Cell Transplantation | 2 | 2011 | 39 | 0.430 |
Why?
|
| Muscles | 5 | 2020 | 171 | 0.430 |
Why?
|
| Promoter Regions, Genetic | 9 | 2008 | 661 | 0.430 |
Why?
|
| Plasmids | 9 | 2016 | 283 | 0.430 |
Why?
|
| Simplexvirus | 2 | 2010 | 25 | 0.420 |
Why?
|
| Mice, Knockout | 13 | 2020 | 1998 | 0.410 |
Why?
|
| MicroRNAs | 5 | 2017 | 620 | 0.410 |
Why?
|
| Genome, Viral | 9 | 2010 | 122 | 0.410 |
Why?
|
| Models, Biological | 3 | 2016 | 1143 | 0.410 |
Why?
|
| Cytokines | 5 | 2010 | 911 | 0.410 |
Why?
|
| Sudden Infant Death | 1 | 2012 | 20 | 0.400 |
Why?
|
| Autoimmunity | 4 | 2010 | 221 | 0.390 |
Why?
|
| Butyryl-CoA Dehydrogenase | 2 | 2008 | 2 | 0.370 |
Why?
|
| Agammaglobulinemia | 1 | 2011 | 8 | 0.370 |
Why?
|
| Basal Ganglia | 1 | 2011 | 30 | 0.370 |
Why?
|
| Gene Silencing | 3 | 2017 | 379 | 0.370 |
Why?
|
| Axonal Transport | 1 | 2011 | 31 | 0.370 |
Why?
|
| Medicine | 2 | 2022 | 56 | 0.360 |
Why?
|
| Health Care Reform | 1 | 2011 | 88 | 0.360 |
Why?
|
| Sendai virus | 1 | 2010 | 13 | 0.360 |
Why?
|
| Mice, Transgenic | 8 | 2020 | 1226 | 0.360 |
Why?
|
| Virus Integration | 5 | 2013 | 32 | 0.350 |
Why?
|
| CD3 Complex | 1 | 2010 | 64 | 0.350 |
Why?
|
| Metabolism, Inborn Errors | 2 | 2008 | 21 | 0.350 |
Why?
|
| Substance-Related Disorders | 1 | 2017 | 690 | 0.340 |
Why?
|
| Lymphocytes | 2 | 2010 | 194 | 0.340 |
Why?
|
| Bone Diseases, Endocrine | 1 | 2009 | 1 | 0.340 |
Why?
|
| Interleukin-13 | 1 | 2009 | 35 | 0.330 |
Why?
|
| Adult | 20 | 2024 | 15980 | 0.330 |
Why?
|
| Child | 9 | 2024 | 4332 | 0.330 |
Why?
|
| Stem Cell Transplantation | 2 | 2007 | 75 | 0.320 |
Why?
|
| Interleukin-17 | 1 | 2009 | 82 | 0.320 |
Why?
|
| China | 2 | 2021 | 140 | 0.320 |
Why?
|
| Infant | 3 | 2024 | 1532 | 0.320 |
Why?
|
| Mutagenesis, Insertional | 3 | 2017 | 88 | 0.320 |
Why?
|
| Endovascular Procedures | 1 | 2015 | 581 | 0.320 |
Why?
|
| Alleles | 4 | 2024 | 423 | 0.310 |
Why?
|
| Carcinogenesis | 2 | 2021 | 118 | 0.300 |
Why?
|
| Ganglia, Spinal | 1 | 2008 | 24 | 0.290 |
Why?
|
| Anniversaries and Special Events | 2 | 2017 | 14 | 0.290 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2015 | 169 | 0.290 |
Why?
|
| Leber Congenital Amaurosis | 2 | 2018 | 4 | 0.290 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2007 | 7 | 0.290 |
Why?
|
| Diabetes Mellitus | 2 | 2009 | 537 | 0.280 |
Why?
|
| Bronchoalveolar Lavage Fluid | 4 | 2006 | 98 | 0.280 |
Why?
|
| DNA-Binding Proteins | 3 | 2004 | 1136 | 0.280 |
Why?
|
| Carnitine | 4 | 2019 | 21 | 0.280 |
Why?
|
| Time Factors | 13 | 2017 | 3619 | 0.280 |
Why?
|
| Eye Proteins | 4 | 2008 | 73 | 0.280 |
Why?
|
| Internship and Residency | 3 | 2020 | 748 | 0.280 |
Why?
|
| Retinal Degeneration | 2 | 2018 | 28 | 0.280 |
Why?
|
| Animals, Newborn | 7 | 2017 | 230 | 0.280 |
Why?
|
| Rats | 18 | 2013 | 1914 | 0.280 |
Why?
|
| Swine | 2 | 2018 | 349 | 0.280 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2006 | 4 | 0.270 |
Why?
|
| Antibodies, Viral | 6 | 2009 | 302 | 0.270 |
Why?
|
| Human Experimentation | 1 | 2006 | 33 | 0.270 |
Why?
|
| Parvoviridae Infections | 3 | 2005 | 23 | 0.270 |
Why?
|
| Exons | 2 | 2021 | 193 | 0.260 |
Why?
|
| Pyruvate Dehydrogenase Complex | 2 | 2003 | 4 | 0.260 |
Why?
|
| Motor Neurons | 1 | 2008 | 206 | 0.260 |
Why?
|
| Lymphocyte Activation | 3 | 2017 | 742 | 0.260 |
Why?
|
| Pyruvate Dehydrogenase Complex Deficiency Disease | 2 | 2003 | 3 | 0.260 |
Why?
|
| cis-trans-Isomerases | 6 | 2018 | 7 | 0.260 |
Why?
|
| Veins | 2 | 2017 | 61 | 0.260 |
Why?
|
| Bronchial Neoplasms | 1 | 2006 | 6 | 0.260 |
Why?
|
| Base Sequence | 12 | 2016 | 1307 | 0.260 |
Why?
|
| Gene Targeting | 2 | 2021 | 82 | 0.260 |
Why?
|
| Carcinoid Tumor | 1 | 2006 | 14 | 0.250 |
Why?
|
| Pneumonia | 2 | 2006 | 272 | 0.250 |
Why?
|
| Schools, Medical | 3 | 2022 | 145 | 0.250 |
Why?
|
| Luminescent Proteins | 7 | 2004 | 129 | 0.250 |
Why?
|
| Tissue Distribution | 5 | 2012 | 286 | 0.250 |
Why?
|
| Mitochondria | 6 | 2006 | 337 | 0.250 |
Why?
|
| Pancreatic Ducts | 1 | 2005 | 30 | 0.250 |
Why?
|
| Rabbits | 11 | 2007 | 329 | 0.250 |
Why?
|
| Respiratory Mucosa | 3 | 2016 | 53 | 0.250 |
Why?
|
| Liver Neoplasms | 3 | 2015 | 279 | 0.240 |
Why?
|
| Blindness | 4 | 2008 | 37 | 0.230 |
Why?
|
| Immune System | 3 | 2010 | 129 | 0.230 |
Why?
|
| Fatty Acids | 1 | 2006 | 194 | 0.230 |
Why?
|
| Models, Animal | 5 | 2019 | 222 | 0.230 |
Why?
|
| Immunophenotyping | 2 | 2017 | 185 | 0.230 |
Why?
|
| Gene Expression Regulation, Viral | 3 | 2004 | 47 | 0.230 |
Why?
|
| Founder Effect | 1 | 2024 | 11 | 0.220 |
Why?
|
| Biopsy | 2 | 2017 | 376 | 0.220 |
Why?
|
| INDEL Mutation | 1 | 2024 | 18 | 0.220 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2012 | 524 | 0.220 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 61 | 0.220 |
Why?
|
| Endopeptidases | 1 | 2024 | 68 | 0.220 |
Why?
|
| RNA, Messenger | 9 | 2007 | 1469 | 0.220 |
Why?
|
| Gene Products, tat | 1 | 2003 | 14 | 0.220 |
Why?
|
| Mitochondria, Liver | 1 | 2003 | 11 | 0.220 |
Why?
|
| Fatal Outcome | 1 | 2023 | 115 | 0.210 |
Why?
|
| Virus Latency | 3 | 1999 | 29 | 0.210 |
Why?
|
| Blood-Brain Barrier | 1 | 2024 | 81 | 0.210 |
Why?
|
| Antibody Formation | 3 | 2003 | 112 | 0.210 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2016 | 257 | 0.210 |
Why?
|
| Genetic Research | 1 | 2023 | 8 | 0.210 |
Why?
|
| Apolipoproteins E | 1 | 2003 | 99 | 0.210 |
Why?
|
| Membrane Proteins | 6 | 2003 | 845 | 0.210 |
Why?
|
| Massachusetts | 2 | 2020 | 2119 | 0.210 |
Why?
|
| Pyruvate Dehydrogenase (Lipoamide) | 1 | 2002 | 1 | 0.210 |
Why?
|
| Patients | 1 | 2023 | 103 | 0.200 |
Why?
|
| Pulmonary Emphysema | 2 | 2018 | 87 | 0.200 |
Why?
|
| Serotyping | 4 | 2008 | 50 | 0.200 |
Why?
|
| Spleen | 5 | 2010 | 486 | 0.200 |
Why?
|
| Mice, SCID | 4 | 2020 | 509 | 0.200 |
Why?
|
| Luciferases | 3 | 2009 | 109 | 0.200 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 1564 | 0.190 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2001 | 31 | 0.190 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 102 | 0.190 |
Why?
|
| Prealbumin | 1 | 2021 | 20 | 0.190 |
Why?
|
| Electron Transport Complex I | 4 | 2011 | 16 | 0.190 |
Why?
|
| Injections | 2 | 2020 | 79 | 0.190 |
Why?
|
| Anticonvulsants | 1 | 2022 | 94 | 0.190 |
Why?
|
| Liposomes | 4 | 2013 | 100 | 0.180 |
Why?
|
| Flow Cytometry | 3 | 2010 | 636 | 0.180 |
Why?
|
| Precision Medicine | 1 | 2022 | 105 | 0.180 |
Why?
|
| Pseudomonas Infections | 3 | 2010 | 52 | 0.180 |
Why?
|
| Interleukin-4 | 4 | 2008 | 141 | 0.180 |
Why?
|
| Viruses | 1 | 2002 | 79 | 0.180 |
Why?
|
| Neoplasms | 2 | 2021 | 1261 | 0.180 |
Why?
|
| Mice, Inbred NOD | 8 | 2020 | 516 | 0.180 |
Why?
|
| Immunity, Innate | 2 | 2023 | 766 | 0.180 |
Why?
|
| Heart | 1 | 2023 | 276 | 0.180 |
Why?
|
| Immunity, Cellular | 5 | 2020 | 176 | 0.180 |
Why?
|
| Phylogeny | 2 | 2013 | 334 | 0.180 |
Why?
|
| Politics | 1 | 2020 | 32 | 0.180 |
Why?
|
| Administration, Intranasal | 4 | 2005 | 28 | 0.180 |
Why?
|
| Drug Delivery Systems | 2 | 2002 | 311 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2017 | 237 | 0.170 |
Why?
|
| Insulin | 5 | 2005 | 688 | 0.170 |
Why?
|
| Physicians, Women | 1 | 2020 | 42 | 0.170 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2021 | 137 | 0.170 |
Why?
|
| Sheep | 3 | 2020 | 168 | 0.170 |
Why?
|
| Specialization | 1 | 2020 | 75 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2024 | 2052 | 0.170 |
Why?
|
| Global Health | 1 | 2021 | 165 | 0.170 |
Why?
|
| Cisterna Magna | 1 | 2019 | 14 | 0.170 |
Why?
|
| Thalamus | 1 | 2020 | 65 | 0.170 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2019 | 34 | 0.170 |
Why?
|
| Nicotine | 1 | 2000 | 111 | 0.160 |
Why?
|
| Graft Survival | 5 | 2017 | 279 | 0.160 |
Why?
|
| Saccharomyces cerevisiae Proteins | 3 | 2011 | 420 | 0.160 |
Why?
|
| Adolescent | 10 | 2018 | 5957 | 0.160 |
Why?
|
| Pan troglodytes | 2 | 2009 | 35 | 0.160 |
Why?
|
| Caspase 3 | 2 | 2012 | 104 | 0.160 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 361 | 0.160 |
Why?
|
| Actins | 3 | 2008 | 258 | 0.160 |
Why?
|
| Capital Financing | 1 | 2019 | 3 | 0.160 |
Why?
|
| Heart Rate | 1 | 2000 | 308 | 0.160 |
Why?
|
| Reference Standards | 2 | 2017 | 61 | 0.160 |
Why?
|
| Th2 Cells | 2 | 2009 | 98 | 0.160 |
Why?
|
| Cell Proliferation | 3 | 2008 | 943 | 0.160 |
Why?
|
| Primates | 1 | 2018 | 42 | 0.160 |
Why?
|
| Oxygen | 1 | 2000 | 309 | 0.160 |
Why?
|
| Protein Transport | 4 | 2012 | 398 | 0.150 |
Why?
|
| Biotechnology | 1 | 2019 | 42 | 0.150 |
Why?
|
| HEK293 Cells | 4 | 2021 | 582 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 164 | 0.150 |
Why?
|
| Chloride Channels | 5 | 2004 | 28 | 0.150 |
Why?
|
| Mice, Inbred CFTR | 2 | 2008 | 3 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2012 | 805 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 45 | 0.150 |
Why?
|
| Haplorhini | 1 | 2018 | 14 | 0.150 |
Why?
|
| Molecular Sequence Data | 10 | 2012 | 1973 | 0.150 |
Why?
|
| Autoantibodies | 3 | 2010 | 174 | 0.150 |
Why?
|
| Blood Pressure | 1 | 2000 | 522 | 0.150 |
Why?
|
| Organizational Policy | 1 | 2018 | 54 | 0.150 |
Why?
|
| Germany | 1 | 2017 | 53 | 0.150 |
Why?
|
| Mosquito Vectors | 1 | 2017 | 11 | 0.140 |
Why?
|
| Patient Safety | 2 | 2018 | 244 | 0.140 |
Why?
|
| Ferrets | 1 | 2017 | 5 | 0.140 |
Why?
|
| Medical Staff, Hospital | 1 | 2018 | 59 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 191 | 0.140 |
Why?
|
| Blotting, Southern | 4 | 2009 | 52 | 0.140 |
Why?
|
| Oncolytic Viruses | 1 | 2017 | 7 | 0.140 |
Why?
|
| Gammaretrovirus | 1 | 2017 | 7 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 203 | 0.140 |
Why?
|
| Neonatal Screening | 1 | 2018 | 96 | 0.140 |
Why?
|
| Europe | 1 | 2017 | 184 | 0.140 |
Why?
|
| Islets of Langerhans Transplantation | 3 | 2003 | 170 | 0.140 |
Why?
|
| Genetic Variation | 1 | 2019 | 366 | 0.140 |
Why?
|
| Drug Approval | 1 | 2017 | 27 | 0.140 |
Why?
|
| Orbit | 1 | 2017 | 17 | 0.140 |
Why?
|
| Organizational Culture | 1 | 2018 | 111 | 0.140 |
Why?
|
| Asthma | 2 | 2012 | 423 | 0.140 |
Why?
|
| Enzyme Assays | 1 | 2017 | 14 | 0.140 |
Why?
|
| Superoxide Dismutase | 2 | 2017 | 214 | 0.140 |
Why?
|
| Respiratory Insufficiency | 1 | 2019 | 155 | 0.140 |
Why?
|
| Italy | 1 | 2016 | 63 | 0.130 |
Why?
|
| Carrier Proteins | 4 | 2008 | 704 | 0.130 |
Why?
|
| Societies, Scientific | 1 | 2016 | 32 | 0.130 |
Why?
|
| Review Literature as Topic | 1 | 2016 | 33 | 0.130 |
Why?
|
| Antigens, Viral | 1 | 2017 | 133 | 0.130 |
Why?
|
| Glycomics | 1 | 2016 | 4 | 0.130 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2017 | 178 | 0.130 |
Why?
|
| France | 1 | 2016 | 11 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2018 | 5264 | 0.130 |
Why?
|
| Education, Professional | 1 | 2016 | 12 | 0.130 |
Why?
|
| Bronchoscopy | 3 | 2006 | 79 | 0.130 |
Why?
|
| Health Facilities, Proprietary | 1 | 2015 | 4 | 0.130 |
Why?
|
| Interleukins | 2 | 2008 | 78 | 0.130 |
Why?
|
| CD52 Antigen | 1 | 2015 | 4 | 0.130 |
Why?
|
| Intellectual Property | 1 | 2015 | 6 | 0.130 |
Why?
|
| RNA, Small Interfering | 3 | 2013 | 855 | 0.130 |
Why?
|
| Environment | 1 | 2016 | 125 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 5 | 2006 | 876 | 0.130 |
Why?
|
| NADH Dehydrogenase | 2 | 2006 | 5 | 0.120 |
Why?
|
| Spinal Cord | 3 | 2008 | 197 | 0.120 |
Why?
|
| Terminal Repeat Sequences | 1 | 2015 | 14 | 0.120 |
Why?
|
| Lipid Metabolism | 2 | 2019 | 203 | 0.120 |
Why?
|
| Arteries | 1 | 2015 | 75 | 0.120 |
Why?
|
| Antigens, Neoplasm | 1 | 2015 | 136 | 0.120 |
Why?
|
| Mental Disorders | 1 | 2022 | 770 | 0.120 |
Why?
|
| Mice, Mutant Strains | 3 | 2017 | 304 | 0.120 |
Why?
|
| HeLa Cells | 4 | 2021 | 531 | 0.120 |
Why?
|
| Cytomegalovirus | 2 | 2008 | 89 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2009 | 621 | 0.110 |
Why?
|
| Glycoproteins | 1 | 2015 | 194 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2015 | 344 | 0.110 |
Why?
|
| Incidence | 1 | 2018 | 1266 | 0.110 |
Why?
|
| Cloning, Molecular | 2 | 2005 | 381 | 0.110 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2013 | 4 | 0.110 |
Why?
|
| Phenotype | 2 | 2012 | 1157 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2019 | 699 | 0.110 |
Why?
|
| Clone Cells | 1 | 2013 | 106 | 0.110 |
Why?
|
| Infant, Newborn | 1 | 2018 | 1312 | 0.110 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2017 | 477 | 0.110 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 434 | 0.110 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 1383 | 0.110 |
Why?
|
| Mucopolysaccharidosis VII | 1 | 2013 | 2 | 0.110 |
Why?
|
| Ornithine Carbamoyltransferase | 1 | 2013 | 4 | 0.110 |
Why?
|
| Canavan Disease | 1 | 2013 | 11 | 0.110 |
Why?
|
| Amidohydrolases | 1 | 2013 | 35 | 0.110 |
Why?
|
| Peptides | 1 | 2017 | 550 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2013 | 112 | 0.100 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2013 | 113 | 0.100 |
Why?
|
| Apoptosis | 3 | 2009 | 1040 | 0.100 |
Why?
|
| DNA-Activated Protein Kinase | 2 | 2004 | 12 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 483 | 0.100 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2022 | 86 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2011 | 275 | 0.100 |
Why?
|
| Aerosols | 2 | 2003 | 44 | 0.100 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 27 | 0.100 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2012 | 31 | 0.100 |
Why?
|
| Clinical Protocols | 4 | 2004 | 137 | 0.100 |
Why?
|
| Parkinson Disease | 4 | 2007 | 118 | 0.100 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2001 | 14 | 0.100 |
Why?
|
| Group IV Phospholipases A2 | 1 | 2012 | 5 | 0.100 |
Why?
|
| Immunoblotting | 4 | 2012 | 190 | 0.100 |
Why?
|
| Gene Order | 1 | 2012 | 29 | 0.100 |
Why?
|
| Melanocytes | 2 | 2009 | 78 | 0.100 |
Why?
|
| Biological Transport | 2 | 2004 | 287 | 0.100 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2011 | 152 | 0.100 |
Why?
|
| Biomarkers | 1 | 2017 | 1212 | 0.100 |
Why?
|
| Vision, Ocular | 2 | 2008 | 17 | 0.100 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2011 | 12 | 0.100 |
Why?
|
| Analysis of Variance | 2 | 2010 | 576 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2011 | 570 | 0.100 |
Why?
|
| Creatine Kinase | 1 | 2011 | 41 | 0.100 |
Why?
|
| Respiratory Function Tests | 2 | 2006 | 165 | 0.090 |
Why?
|
| Purkinje Cells | 1 | 2011 | 5 | 0.090 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 295 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 193 | 0.090 |
Why?
|
| Troleandomycin | 1 | 1991 | 1 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 3 | 2003 | 454 | 0.090 |
Why?
|
| Cell Fusion | 1 | 2011 | 45 | 0.090 |
Why?
|
| Maxillary Sinusitis | 3 | 2002 | 4 | 0.090 |
Why?
|
| Creatinine | 2 | 2008 | 123 | 0.090 |
Why?
|
| Epitopes | 2 | 2010 | 295 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 2 | 2007 | 665 | 0.090 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2011 | 13 | 0.090 |
Why?
|
| Myocardium | 1 | 2013 | 263 | 0.090 |
Why?
|
| Mannose-6-Phosphate Isomerase | 1 | 2010 | 1 | 0.090 |
Why?
|
| Frameshift Mutation | 1 | 2010 | 29 | 0.090 |
Why?
|
| NFATC Transcription Factors | 1 | 2010 | 20 | 0.090 |
Why?
|
| Aspergillus | 1 | 2010 | 10 | 0.090 |
Why?
|
| Mannose | 1 | 2010 | 21 | 0.090 |
Why?
|
| Virus Shedding | 2 | 2003 | 17 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 96 | 0.090 |
Why?
|
| DNA, Mitochondrial | 2 | 2001 | 78 | 0.090 |
Why?
|
| Nevus | 2 | 2009 | 18 | 0.090 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2008 | 194 | 0.090 |
Why?
|
| Glycosylation | 1 | 2010 | 134 | 0.090 |
Why?
|
| Cell Separation | 1 | 2010 | 147 | 0.090 |
Why?
|
| Genomics | 1 | 2013 | 314 | 0.090 |
Why?
|
| In Vitro Techniques | 3 | 2002 | 472 | 0.090 |
Why?
|
| CD11b Antigen | 1 | 2009 | 21 | 0.080 |
Why?
|
| Optic Atrophy, Hereditary, Leber | 2 | 2006 | 2 | 0.080 |
Why?
|
| Simian virus 40 | 1 | 2009 | 17 | 0.080 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2007 | 130 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2008 | 677 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2021 | 3131 | 0.080 |
Why?
|
| Middle Aged | 6 | 2017 | 16540 | 0.080 |
Why?
|
| Polymorphism, Genetic | 2 | 2017 | 194 | 0.080 |
Why?
|
| Interferon-gamma | 1 | 2011 | 550 | 0.080 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2009 | 2 | 0.080 |
Why?
|
| Pneumonia, Bacterial | 1 | 2010 | 87 | 0.080 |
Why?
|
| Melanoma | 2 | 2009 | 335 | 0.080 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2009 | 21 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 584 | 0.080 |
Why?
|
| Targeted Gene Repair | 1 | 2008 | 3 | 0.080 |
Why?
|
| CD4 Antigens | 1 | 2009 | 156 | 0.080 |
Why?
|
| Kidney | 4 | 2007 | 397 | 0.080 |
Why?
|
| Double-Blind Method | 3 | 2002 | 680 | 0.080 |
Why?
|
| Species Specificity | 1 | 2009 | 334 | 0.080 |
Why?
|
| Organ Specificity | 3 | 2020 | 181 | 0.080 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2009 | 53 | 0.080 |
Why?
|
| Isomerases | 1 | 2008 | 4 | 0.080 |
Why?
|
| Saccharomyces cerevisiae | 2 | 2011 | 530 | 0.080 |
Why?
|
| Retinoids | 1 | 2008 | 12 | 0.080 |
Why?
|
| Splenomegaly | 1 | 2008 | 23 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 3 | 2000 | 400 | 0.080 |
Why?
|
| Blotting, Western | 2 | 2007 | 594 | 0.080 |
Why?
|
| Genes, Recessive | 1 | 2008 | 52 | 0.080 |
Why?
|
| Sciatic Nerve | 2 | 2006 | 23 | 0.080 |
Why?
|
| Retinal Rod Photoreceptor Cells | 1 | 2008 | 21 | 0.080 |
Why?
|
| Biological Evolution | 1 | 2009 | 111 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 1 | 2008 | 29 | 0.080 |
Why?
|
| Phosphotransferases | 1 | 2008 | 21 | 0.080 |
Why?
|
| Leadership | 2 | 2021 | 200 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2008 | 37 | 0.080 |
Why?
|
| Pregnancy, Animal | 1 | 2008 | 10 | 0.080 |
Why?
|
| Abdomen | 1 | 1988 | 92 | 0.080 |
Why?
|
| Antigens, Fungal | 1 | 2008 | 55 | 0.080 |
Why?
|
| Video Recording | 2 | 2019 | 126 | 0.080 |
Why?
|
| Transplantation, Heterologous | 2 | 2020 | 225 | 0.070 |
Why?
|
| Complex Mixtures | 1 | 2008 | 5 | 0.070 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2008 | 20 | 0.070 |
Why?
|
| Concanavalin A | 1 | 2008 | 40 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 1 | 2008 | 45 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2008 | 49 | 0.070 |
Why?
|
| Pyramidal Tracts | 1 | 2008 | 25 | 0.070 |
Why?
|
| Osteogenesis | 1 | 2009 | 150 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2007 | 305 | 0.070 |
Why?
|
| Hyperglycemia | 1 | 2008 | 104 | 0.070 |
Why?
|
| Injections, Intraocular | 2 | 2018 | 4 | 0.070 |
Why?
|
| Aorta | 2 | 2005 | 106 | 0.070 |
Why?
|
| Mutant Proteins | 1 | 2008 | 105 | 0.070 |
Why?
|
| Helper Viruses | 3 | 2010 | 4 | 0.070 |
Why?
|
| Risk Factors | 1 | 2017 | 5086 | 0.070 |
Why?
|
| Fatty Liver | 1 | 2008 | 96 | 0.070 |
Why?
|
| Vitamin B 12 | 1 | 2007 | 25 | 0.070 |
Why?
|
| Visual Fields | 2 | 2018 | 43 | 0.070 |
Why?
|
| Graft Rejection | 2 | 2007 | 264 | 0.070 |
Why?
|
| Cell Nucleus | 2 | 2001 | 604 | 0.070 |
Why?
|
| Smoking | 1 | 2012 | 835 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 1988 | 160 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2008 | 365 | 0.070 |
Why?
|
| Aged | 4 | 2017 | 13581 | 0.070 |
Why?
|
| Hepatectomy | 2 | 2004 | 59 | 0.070 |
Why?
|
| Calcium | 1 | 2010 | 559 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2008 | 98 | 0.070 |
Why?
|
| Caspase Inhibitors | 1 | 2006 | 21 | 0.070 |
Why?
|
| Parental Consent | 1 | 2006 | 7 | 0.070 |
Why?
|
| Receptors, Virus | 2 | 2004 | 82 | 0.070 |
Why?
|
| Visual Acuity | 2 | 2018 | 118 | 0.070 |
Why?
|
| Neuralgia | 1 | 2006 | 20 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2008 | 256 | 0.070 |
Why?
|
| Hepatitis C | 1 | 2008 | 140 | 0.070 |
Why?
|
| Retroviridae | 2 | 1999 | 72 | 0.070 |
Why?
|
| Trypsin Inhibitors | 1 | 2006 | 3 | 0.070 |
Why?
|
| Lysosomal Storage Diseases | 2 | 2007 | 14 | 0.070 |
Why?
|
| Immunity, Humoral | 2 | 2020 | 41 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 570 | 0.060 |
Why?
|
| Enzyme Inhibitors | 2 | 2005 | 346 | 0.060 |
Why?
|
| Adenoviruses, Human | 2 | 1998 | 9 | 0.060 |
Why?
|
| Neurons | 2 | 2002 | 863 | 0.060 |
Why?
|
| Allergens | 1 | 2006 | 45 | 0.060 |
Why?
|
| Nasal Cavity | 1 | 2005 | 10 | 0.060 |
Why?
|
| Rats, Inbred F344 | 1 | 2005 | 52 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 1481 | 0.060 |
Why?
|
| Models, Molecular | 2 | 2007 | 1136 | 0.060 |
Why?
|
| Pain | 1 | 1988 | 403 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 129 | 0.060 |
Why?
|
| Oxygenases | 1 | 2005 | 8 | 0.060 |
Why?
|
| Pancreatic Elastase | 2 | 2006 | 31 | 0.060 |
Why?
|
| Proteasome Inhibitors | 1 | 2005 | 30 | 0.060 |
Why?
|
| Sciatica | 1 | 2005 | 4 | 0.060 |
Why?
|
| Secondary Prevention | 2 | 2003 | 154 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2009 | 2892 | 0.060 |
Why?
|
| DNA Primers | 3 | 2007 | 292 | 0.060 |
Why?
|
| Radiography, Thoracic | 1 | 2006 | 102 | 0.060 |
Why?
|
| Pneumonectomy | 1 | 2006 | 84 | 0.060 |
Why?
|
| Disease Progression | 1 | 2009 | 1054 | 0.060 |
Why?
|
| Cell Polarity | 1 | 2005 | 110 | 0.060 |
Why?
|
| DNA, Complementary | 5 | 2009 | 166 | 0.060 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 305 | 0.060 |
Why?
|
| Heat-Shock Proteins | 1 | 2005 | 66 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2006 | 158 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 454 | 0.060 |
Why?
|
| Pancreas | 1 | 2005 | 146 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2005 | 1850 | 0.060 |
Why?
|
| Research Design | 1 | 2008 | 569 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 113 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2009 | 651 | 0.060 |
Why?
|
| Amino Acid Sequence | 3 | 2017 | 1580 | 0.060 |
Why?
|
| Genes, Synthetic | 1 | 2004 | 5 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2007 | 268 | 0.060 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2005 | 60 | 0.060 |
Why?
|
| Endocytosis | 1 | 2005 | 148 | 0.060 |
Why?
|
| Mass Spectrometry | 1 | 2006 | 288 | 0.060 |
Why?
|
| Cell Membrane | 2 | 2005 | 492 | 0.060 |
Why?
|
| Virion | 1 | 2005 | 123 | 0.060 |
Why?
|
| Sleep Deprivation | 1 | 2004 | 16 | 0.060 |
Why?
|
| Methylphenidate | 1 | 2004 | 18 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2009 | 404 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2008 | 2360 | 0.060 |
Why?
|
| Recurrence | 1 | 2006 | 600 | 0.060 |
Why?
|
| Insulin-Secreting Cells | 1 | 2005 | 177 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2006 | 370 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2005 | 170 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 171 | 0.050 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2003 | 32 | 0.050 |
Why?
|
| Central Nervous System Stimulants | 1 | 2004 | 63 | 0.050 |
Why?
|
| Aging | 1 | 2009 | 731 | 0.050 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2003 | 13 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 71 | 0.050 |
Why?
|
| Viremia | 1 | 2003 | 44 | 0.050 |
Why?
|
| DNA, Single-Stranded | 1 | 2004 | 100 | 0.050 |
Why?
|
| Kidney Tubules | 1 | 2003 | 18 | 0.050 |
Why?
|
| Sex Factors | 2 | 2021 | 970 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 910 | 0.050 |
Why?
|
| Education, Continuing | 1 | 2022 | 24 | 0.050 |
Why?
|
| Papio | 1 | 2002 | 13 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2006 | 1470 | 0.050 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2002 | 18 | 0.050 |
Why?
|
| Maxillary Sinus | 1 | 2002 | 2 | 0.050 |
Why?
|
| Chlorides | 2 | 1993 | 32 | 0.050 |
Why?
|
| Gonads | 1 | 2002 | 15 | 0.050 |
Why?
|
| Faculty | 1 | 2022 | 53 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 1100 | 0.050 |
Why?
|
| Cricetulus | 1 | 2022 | 102 | 0.050 |
Why?
|
| CHO Cells | 1 | 2022 | 190 | 0.050 |
Why?
|
| Pregnancy | 2 | 2008 | 2359 | 0.050 |
Why?
|
| Weight Loss | 1 | 2004 | 264 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 1996 | 155 | 0.050 |
Why?
|
| Pulmonary Alveoli | 2 | 2006 | 44 | 0.050 |
Why?
|
| Cell Line, Transformed | 2 | 1999 | 97 | 0.050 |
Why?
|
| Cricetinae | 1 | 2022 | 376 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2002 | 293 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 95 | 0.050 |
Why?
|
| Hemangiosarcoma | 1 | 2001 | 24 | 0.050 |
Why?
|
| Factor X | 1 | 2001 | 2 | 0.050 |
Why?
|
| Peptide Elongation Factor 1 | 1 | 2001 | 4 | 0.050 |
Why?
|
| Molecular Epidemiology | 1 | 2021 | 26 | 0.050 |
Why?
|
| Hemophilia A | 1 | 2001 | 56 | 0.050 |
Why?
|
| Thinking | 1 | 2001 | 28 | 0.050 |
Why?
|
| Quinone Reductases | 1 | 2000 | 11 | 0.050 |
Why?
|
| Defensins | 1 | 2000 | 5 | 0.050 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2000 | 7 | 0.050 |
Why?
|
| Problem-Based Learning | 1 | 2001 | 35 | 0.040 |
Why?
|
| Acidosis, Lactic | 1 | 2000 | 11 | 0.040 |
Why?
|
| Glucose | 1 | 2003 | 447 | 0.040 |
Why?
|
| Deoxyribonucleases | 1 | 2000 | 30 | 0.040 |
Why?
|
| Endonucleases | 1 | 2021 | 81 | 0.040 |
Why?
|
| Nucleic Acids | 1 | 2001 | 50 | 0.040 |
Why?
|
| Mitochondrial Proteins | 1 | 2001 | 99 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2001 | 189 | 0.040 |
Why?
|
| Kinetics | 3 | 2006 | 736 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2001 | 227 | 0.040 |
Why?
|
| Transplantation, Homologous | 3 | 2007 | 236 | 0.040 |
Why?
|
| Awards and Prizes | 1 | 2020 | 30 | 0.040 |
Why?
|
| Cognition | 1 | 2004 | 466 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 71 | 0.040 |
Why?
|
| Virus Replication | 2 | 2012 | 307 | 0.040 |
Why?
|
| Teaching | 1 | 2001 | 157 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 735 | 0.040 |
Why?
|
| Defective Viruses | 1 | 1999 | 3 | 0.040 |
Why?
|
| Pharmaceutical Vehicles | 1 | 1999 | 4 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2000 | 253 | 0.040 |
Why?
|
| Airway Obstruction | 1 | 1999 | 35 | 0.040 |
Why?
|
| Research | 1 | 2001 | 190 | 0.040 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2019 | 56 | 0.040 |
Why?
|
| Catheters | 1 | 2019 | 68 | 0.040 |
Why?
|
| Transformation, Genetic | 1 | 1999 | 27 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 760 | 0.040 |
Why?
|
| Career Choice | 1 | 2020 | 114 | 0.040 |
Why?
|
| Adenosine Triphosphatases | 1 | 2000 | 253 | 0.040 |
Why?
|
| Safety | 1 | 1999 | 141 | 0.040 |
Why?
|
| Dogs | 3 | 2006 | 307 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 280 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2020 | 273 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2001 | 319 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 1998 | 20 | 0.040 |
Why?
|
| Sinusitis | 1 | 1998 | 27 | 0.040 |
Why?
|
| Moloney murine leukemia virus | 1 | 1998 | 17 | 0.040 |
Why?
|
| HIV-1 | 1 | 2003 | 709 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 849 | 0.040 |
Why?
|
| Hair Removal | 1 | 1996 | 8 | 0.030 |
Why?
|
| K562 Cells | 1 | 2017 | 58 | 0.030 |
Why?
|
| Lasers | 1 | 1996 | 34 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2017 | 60 | 0.030 |
Why?
|
| Bronchoalveolar Lavage | 1 | 1996 | 13 | 0.030 |
Why?
|
| Hair Follicle | 1 | 1996 | 29 | 0.030 |
Why?
|
| Genes, MDR | 1 | 1996 | 3 | 0.030 |
Why?
|
| Cell Division | 2 | 1995 | 442 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2001 | 568 | 0.030 |
Why?
|
| Glucosylceramidase | 1 | 1996 | 39 | 0.030 |
Why?
|
| Electroretinography | 1 | 2016 | 26 | 0.030 |
Why?
|
| Drug Resistance, Multiple | 1 | 1996 | 33 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2010 | 183 | 0.030 |
Why?
|
| Forecasting | 1 | 1997 | 221 | 0.030 |
Why?
|
| Mutagenesis | 1 | 1996 | 129 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 160 | 0.030 |
Why?
|
| Peptide Chain Initiation, Translational | 1 | 1995 | 20 | 0.030 |
Why?
|
| HIV Long Terminal Repeat | 1 | 1995 | 12 | 0.030 |
Why?
|
| Codon | 1 | 1995 | 49 | 0.030 |
Why?
|
| Lac Operon | 1 | 1995 | 26 | 0.030 |
Why?
|
| Eukaryotic Cells | 1 | 1995 | 56 | 0.030 |
Why?
|
| Mice, Inbred Strains | 2 | 2006 | 182 | 0.030 |
Why?
|
| RNA, Viral | 1 | 1996 | 265 | 0.030 |
Why?
|
| Binding Sites | 2 | 2012 | 872 | 0.030 |
Why?
|
| Amino Acid Substitution | 2 | 2009 | 252 | 0.030 |
Why?
|
| Radiography | 1 | 1996 | 514 | 0.030 |
Why?
|
| Heme Oxygenase (Decyclizing) | 2 | 2005 | 8 | 0.030 |
Why?
|
| Endothelial Cells | 2 | 2006 | 177 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1997 | 435 | 0.030 |
Why?
|
| Rats, Inbred Lew | 2 | 2005 | 110 | 0.030 |
Why?
|
| Nasal Polyps | 1 | 1993 | 9 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2501 | 0.030 |
Why?
|
| Psychophysiologic Disorders | 1 | 1993 | 7 | 0.030 |
Why?
|
| Respiratory Sounds | 1 | 1993 | 20 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 1994 | 143 | 0.030 |
Why?
|
| Genome | 1 | 2016 | 253 | 0.030 |
Why?
|
| X-Ray Diffraction | 1 | 2013 | 58 | 0.030 |
Why?
|
| Iodide Peroxidase | 1 | 2013 | 23 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2013 | 88 | 0.030 |
Why?
|
| Adnexal Diseases | 1 | 1993 | 8 | 0.030 |
Why?
|
| Dihematoporphyrin Ether | 1 | 1992 | 1 | 0.030 |
Why?
|
| Electrocoagulation | 1 | 1993 | 13 | 0.030 |
Why?
|
| Laser Coagulation | 1 | 1993 | 14 | 0.030 |
Why?
|
| Sequence Deletion | 2 | 2008 | 114 | 0.030 |
Why?
|
| Calnexin | 1 | 2012 | 5 | 0.030 |
Why?
|
| Surgical Instruments | 1 | 1993 | 41 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2013 | 86 | 0.030 |
Why?
|
| Endometrium | 1 | 1992 | 28 | 0.030 |
Why?
|
| Proteostasis Deficiencies | 1 | 2012 | 6 | 0.030 |
Why?
|
| Photochemotherapy | 1 | 1992 | 20 | 0.030 |
Why?
|
| Viral Proteins | 1 | 1995 | 261 | 0.030 |
Why?
|
| Containment of Biohazards | 1 | 2012 | 3 | 0.030 |
Why?
|
| International Cooperation | 1 | 2013 | 81 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1993 | 218 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2012 | 49 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 1995 | 417 | 0.030 |
Why?
|
| Ovary | 1 | 1993 | 96 | 0.030 |
Why?
|
| Oxidoreductases | 1 | 2012 | 65 | 0.030 |
Why?
|
| Caspase 7 | 1 | 2012 | 18 | 0.020 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2012 | 10 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2012 | 63 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2012 | 44 | 0.020 |
Why?
|
| Caspase 6 | 1 | 2012 | 17 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 155 | 0.020 |
Why?
|
| Blood Glucose | 2 | 2006 | 473 | 0.020 |
Why?
|
| RNA, Antisense | 1 | 2012 | 49 | 0.020 |
Why?
|
| Antibodies, Fungal | 1 | 2011 | 11 | 0.020 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 1991 | 8 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 243 | 0.020 |
Why?
|
| Protein Kinases | 1 | 1992 | 139 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2012 | 168 | 0.020 |
Why?
|
| Gene Knock-In Techniques | 1 | 2011 | 34 | 0.020 |
Why?
|
| Light Coagulation | 1 | 1991 | 5 | 0.020 |
Why?
|
| Pigment Epithelium of Eye | 1 | 1991 | 12 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 1991 | 31 | 0.020 |
Why?
|
| Lymphoma | 1 | 1991 | 100 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 1991 | 125 | 0.020 |
Why?
|
| Protein Folding | 1 | 2012 | 261 | 0.020 |
Why?
|
| beta-Galactosidase | 2 | 2005 | 81 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2011 | 125 | 0.020 |
Why?
|
| Cataract | 1 | 1991 | 54 | 0.020 |
Why?
|
| Cholesterol | 1 | 2012 | 255 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 1991 | 68 | 0.020 |
Why?
|
| Biological Assay | 1 | 2010 | 54 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2011 | 232 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 272 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2010 | 292 | 0.020 |
Why?
|
| Schwann Cells | 1 | 2009 | 7 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 1991 | 435 | 0.020 |
Why?
|
| Genes | 2 | 2002 | 96 | 0.020 |
Why?
|
| Risk Assessment | 1 | 1996 | 1934 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 669 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2009 | 53 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2009 | 34 | 0.020 |
Why?
|
| Sphingolipids | 1 | 2009 | 23 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 1139 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2009 | 83 | 0.020 |
Why?
|
| Dark Adaptation | 1 | 2008 | 8 | 0.020 |
Why?
|
| Cycloheximide | 1 | 2008 | 21 | 0.020 |
Why?
|
| Leupeptins | 1 | 2008 | 16 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2008 | 21 | 0.020 |
Why?
|
| Retinal Cone Photoreceptor Cells | 1 | 2008 | 25 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2009 | 106 | 0.020 |
Why?
|
| Intubation, Intratracheal | 1 | 2010 | 192 | 0.020 |
Why?
|
| COS Cells | 1 | 2008 | 175 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2008 | 124 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2009 | 156 | 0.020 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2007 | 39 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2009 | 531 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2007 | 9 | 0.020 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2007 | 45 | 0.020 |
Why?
|
| Rats, Inbred WF | 1 | 2007 | 56 | 0.020 |
Why?
|
| Eye Diseases | 1 | 2007 | 37 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 2007 | 152 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 299 | 0.020 |
Why?
|
| Cell-Free System | 1 | 2006 | 31 | 0.020 |
Why?
|
| Hyperesthesia | 1 | 2006 | 1 | 0.020 |
Why?
|
| Mice, Inbred NZB | 1 | 2006 | 19 | 0.020 |
Why?
|
| Mice, Congenic | 1 | 2006 | 22 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2006 | 44 | 0.020 |
Why?
|
| Capillaries | 1 | 2006 | 30 | 0.020 |
Why?
|
| Ligation | 1 | 2006 | 35 | 0.020 |
Why?
|
| Photoreceptor Cells | 1 | 2006 | 20 | 0.020 |
Why?
|
| Microinjections | 1 | 2006 | 66 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2006 | 47 | 0.020 |
Why?
|
| Optic Nerve | 1 | 2006 | 28 | 0.020 |
Why?
|
| Injections, Intralesional | 1 | 2006 | 13 | 0.020 |
Why?
|
| Antibodies, Antinuclear | 1 | 2006 | 36 | 0.020 |
Why?
|
| Uncoupling Agents | 1 | 2006 | 4 | 0.020 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2006 | 3 | 0.020 |
Why?
|
| Rotenone | 1 | 2006 | 10 | 0.020 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2006 | 49 | 0.020 |
Why?
|
| Substantia Nigra | 1 | 2006 | 15 | 0.020 |
Why?
|
| Lupus Nephritis | 1 | 2006 | 33 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2007 | 250 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2006 | 36 | 0.020 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2006 | 36 | 0.020 |
Why?
|
| Lung Injury | 1 | 2006 | 32 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 33 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 4394 | 0.020 |
Why?
|
| Microscopy, Electron | 2 | 2000 | 253 | 0.020 |
Why?
|
| Macrophages | 1 | 2011 | 1015 | 0.020 |
Why?
|
| Half-Life | 1 | 2005 | 70 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2005 | 37 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 116 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2006 | 281 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2007 | 353 | 0.020 |
Why?
|
| 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 2 | 1995 | 6 | 0.020 |
Why?
|
| Neuraminidase | 1 | 2005 | 49 | 0.010 |
Why?
|
| Mitochondrial Encephalomyopathies | 1 | 2004 | 1 | 0.010 |
Why?
|
| Immunochemistry | 1 | 2004 | 11 | 0.010 |
Why?
|
| Proton-Translocating ATPases | 1 | 2004 | 6 | 0.010 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2005 | 80 | 0.010 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2005 | 50 | 0.010 |
Why?
|
| Trachea | 2 | 1995 | 92 | 0.010 |
Why?
|
| Placebos | 1 | 2004 | 71 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2006 | 282 | 0.010 |
Why?
|
| Heparin | 1 | 2005 | 111 | 0.010 |
Why?
|
| Psychological Tests | 1 | 2004 | 50 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2012 | 1459 | 0.010 |
Why?
|
| Fructose-Bisphosphatase | 1 | 2003 | 1 | 0.010 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2003 | 15 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2004 | 165 | 0.010 |
Why?
|
| Insulin Antibodies | 1 | 2003 | 2 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2003 | 49 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2005 | 277 | 0.010 |
Why?
|
| Hospitalization | 1 | 1991 | 1304 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2003 | 12 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2003 | 43 | 0.010 |
Why?
|
| Renal Artery | 1 | 2003 | 29 | 0.010 |
Why?
|
| Heme Oxygenase-1 | 1 | 2003 | 18 | 0.010 |
Why?
|
| Membrane Potentials | 2 | 1994 | 137 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 2002 | 8 | 0.010 |
Why?
|
| Tandem Repeat Sequences | 1 | 2002 | 28 | 0.010 |
Why?
|
| Neurites | 1 | 2002 | 22 | 0.010 |
Why?
|
| Nasal Lavage Fluid | 1 | 2002 | 7 | 0.010 |
Why?
|
| Instillation, Drug | 1 | 2002 | 4 | 0.010 |
Why?
|
| Heparitin Sulfate | 1 | 2002 | 10 | 0.010 |
Why?
|
| Genes, Viral | 1 | 2002 | 56 | 0.010 |
Why?
|
| Microspheres | 1 | 2002 | 55 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 2002 | 111 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2002 | 195 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2002 | 357 | 0.010 |
Why?
|
| Skin | 2 | 1996 | 356 | 0.010 |
Why?
|
| Florida | 1 | 2001 | 41 | 0.010 |
Why?
|
| Chickens | 1 | 2001 | 91 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2000 | 79 | 0.010 |
Why?
|
| Alanine | 1 | 2000 | 46 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 2000 | 49 | 0.010 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2001 | 100 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2000 | 196 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 1999 | 125 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2001 | 309 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1991 | 6136 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2001 | 488 | 0.010 |
Why?
|
| Point Mutation | 1 | 1999 | 164 | 0.010 |
Why?
|
| Patient-Centered Care | 1 | 2001 | 250 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2001 | 632 | 0.010 |
Why?
|
| RNA | 1 | 2001 | 405 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2001 | 847 | 0.010 |
Why?
|
| Curriculum | 1 | 2001 | 570 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 1996 | 17 | 0.010 |
Why?
|
| Harvey murine sarcoma virus | 1 | 1996 | 1 | 0.010 |
Why?
|
| Gene Dosage | 1 | 1996 | 60 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1996 | 108 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1996 | 75 | 0.010 |
Why?
|
| Pulmonary Surfactant-Associated Proteins | 1 | 1995 | 2 | 0.010 |
Why?
|
| Pulmonary Surfactants | 1 | 1995 | 9 | 0.010 |
Why?
|
| Protein Binding | 1 | 2000 | 1555 | 0.010 |
Why?
|
| Keratins | 1 | 1995 | 31 | 0.010 |
Why?
|
| Proteolipids | 1 | 1995 | 24 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1995 | 94 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 1995 | 47 | 0.010 |
Why?
|
| Xenopus | 1 | 1995 | 54 | 0.010 |
Why?
|
| Ion Channel Gating | 1 | 1995 | 44 | 0.010 |
Why?
|
| Patch-Clamp Techniques | 1 | 1995 | 126 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1998 | 744 | 0.010 |
Why?
|
| Calixarenes | 1 | 1994 | 1 | 0.010 |
Why?
|
| Nystatin | 1 | 1994 | 3 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1998 | 685 | 0.010 |
Why?
|
| Thionucleotides | 1 | 1994 | 38 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 1994 | 39 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1995 | 376 | 0.010 |
Why?
|
| Methods | 1 | 1993 | 38 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1994 | 160 | 0.010 |
Why?
|
| Oocytes | 1 | 1995 | 192 | 0.010 |
Why?
|
| Smell | 1 | 1993 | 24 | 0.010 |
Why?
|
| Erbium | 1 | 1993 | 1 | 0.010 |
Why?
|
| Neodymium | 1 | 1993 | 1 | 0.010 |
Why?
|
| Aluminum Silicates | 1 | 1993 | 2 | 0.010 |
Why?
|
| Holmium | 1 | 1993 | 2 | 0.010 |
Why?
|
| Yttrium | 1 | 1993 | 6 | 0.010 |
Why?
|
| Tissue Adhesions | 1 | 1993 | 20 | 0.010 |
Why?
|
| Laryngoscopy | 1 | 1993 | 61 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1992 | 54 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2001 | 2614 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 1993 | 59 | 0.010 |
Why?
|
| Laparotomy | 1 | 1993 | 46 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1993 | 136 | 0.010 |
Why?
|
| Electric Conductivity | 1 | 1992 | 52 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 1993 | 78 | 0.010 |
Why?
|
| Burns | 1 | 1993 | 42 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1993 | 127 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1995 | 630 | 0.010 |
Why?
|
| Reoperation | 1 | 1993 | 269 | 0.010 |
Why?
|
| Genes, ras | 1 | 1991 | 28 | 0.010 |
Why?
|
| Administration, Topical | 1 | 1991 | 51 | 0.010 |
Why?
|
| Ophthalmoscopy | 1 | 1991 | 3 | 0.010 |
Why?
|
| Fluorescein Angiography | 1 | 1991 | 58 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 1992 | 289 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1995 | 688 | 0.010 |
Why?
|